Erudio Healtherudio.com
Drug
Sacituzumab govitecan trials: what clinicians said in public
No HCP commentary report on a trial studying sacituzumab govitecan yet. Erudio has found public clinician commentary on 27 clinical trials studying sacituzumab govitecan, including ASCENT-03, ASCENT-04, TROPHY-U-01 and TROPiCS-02. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| ASCENT-04 NCT05382286 · Gilead Sciences DeepView → | PD-L1-positive previously untreated advanced triple-negative breast cancer | Phase 3 | Deep | View | |||
| ASCENT-03 NCT05382299 · Gilead Sciences DeepView → | previously untreated advanced triple-negative breast cancer | Phase 3 | Deep | View | |||
| TROPiCS-02 NCT03901339 · Gilead Sciences DeepView → | HR+/HER2- metastatic breast cancer | Phase 3 | Deep | View | |||
| TROPHY-U-01 NCT03547973 · Gilead Sciences DeepView → | unresectable locally advanced or metastatic urothelial cancer | Phase 2 | Deep | View | |||
| EVOKE-01 NCT05089734 · Gilead Sciences DeepView → | previously treated advanced or metastatic NSCLC | Phase 3 | Deep | View | |||
| TROPiCS-04 NCT04527991 · Gilead Sciences DeepView → | locally advanced or metastatic unresectable urothelial cancer | Phase 3 | Deep | View | |||
| ASCENT-07 NCT05840211 · Gilead Sciences DeepView → | HR+/HER2- locally advanced or metastatic breast cancer | Phase 3 | Deep | View | |||
| EVOKE-03 NCT05609968 · Merck Sharp & Dohme LLC DeepView → | first-line PD-L1 TPS ≥50% metastatic non-small-cell lung cancer | Phase 3 | Deep | View | |||
| SURE-01 NCT05226117 · IRCCS San Raffaele DeepView → | muscle-invasive bladder cancer | Phase 2 | Deep | View | |||
| EVOKE-02 NCT05186974 · Gilead Sciences DeepView → | first-line advanced/metastatic NSCLC without actionable genomic alterations | Phase 2 | Deep | View | |||
| SATEEN NCT06100874 · Adrienne G. Waks DeepView → | HER2+ metastatic breast cancer after trastuzumab deruxtecan | Phase 2 | Deep | View | |||
| TROPiCS-03 NCT03964727 · Gilead Sciences DeepView → | metastatic solid tumors | Phase 2 | Deep | View | |||
| DAD-IO NCT04724018 · Dana-Farber Cancer Institute DeepView → | metastatic urothelial carcinoma | Phase 1/Phase 2 | Deep | View | |||
| SASCIA NCT04595565 · GBG Forschungs GmbH DeepView → | high relapse risk primary HER2-negative breast cancer | Phase 3 | Deep | View | |||
| IMMU-132-01 NCT01631552 · Gilead Sciences StandardView → | epithelial cancer | Phase 1/Phase 2 | Standard | View | |||
| MORPHEUS-UC NCT03869190 · Hoffmann-La Roche StandardView → | urothelial carcinoma | Phase 1/Phase 2 | Standard | View | |||
| Saci-IO TNBC NCT04468061 · Dana-Farber Cancer Institute StandardView → | PD-L1-negative metastatic triple-negative breast cancer | Phase 2 | Standard | View | |||
| MORPHEUS-panBC NCT03424005 · Hoffmann-La Roche FocusedView → | metastatic breast cancer | Phase 1/Phase 2 | Focused | View | |||
| NCT06248515 NCT06248515 · Georgetown University FocusedView → | advanced thymoma or thymic carcinoma | Phase 2 | Focused | View | |||
| ASPRIA NCT04434040 · Dana-Farber Cancer Institute FocusedView → | triple-negative breast cancer with residual cancer | Phase 2 | Focused | View | |||
| ARIAN NCT06431633 · Fundación GECP FocusedView → | stage IB-IIIA-IIIB(N2) resected non-small cell lung cancer | Phase 3 | Focused | View | |||
| ECOG-ACRIN EA8231 NCT06524544 · National Cancer Institute (NCI) FocusedView → | anti-PD(L)1-resistant advanced urothelial cancer | Phase 3 | Focused | View | |||
| NCT05633654 NCT05633654 · Gilead Sciences FocusedView → | Not given | Phase 3 | Focused | View | |||
| NeoSTAR NCT04230109 · Massachusetts General Hospital FocusedView → | localized triple-negative breast cancer | Phase 2 | Focused | View | |||
| JAVELIN Bladder Medley NCT05327530 · EMD Serono Research & Development Institute, Inc. FocusedView → | first-line maintenance locally advanced or metastatic urothelial carcinoma | Phase 2 | Focused | View | |||
| EVOKE-SCLC-04 NCT06801834 · Gilead Sciences FocusedView → | previously treated extensive stage small cell lung cancer | Phase 3 | Focused | View | |||
| SIMONE NCT06963905 · Yale University FocusedView → | second-line metastatic triple-negative breast cancer | Phase 1/Phase 2 | Focused | View | |||